GlassScriptPhysician profile
Amy Perez
NPI 1376268987
$1,411.87
in general payments reported to CMS, 2019-2025
19 companies · $1,115 in 2025
The $1,115 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $101 · 2024: $197 · 2025: $1,115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,411.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $354.91 | 2025 | Rezdiffra |
| Abbvie INC. | $192.66 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $183.43 | 2025 | Entyvio |
| Ardelyx, INC. | $119.33 | 2023-2025 | Ibsrela |
| Novo Nordisk INC | $87.92 | 2024-2025 | Rybelsus, Wegovy, Ozempic |
| Gilead Sciences, INC. | $54.84 | 2025 | |
| Aimmune Therapeutics, INC. | $50.70 | 2025 | Zenpep |
| Amgen INC. | $47.28 | 2023-2024 | Repatha, Otezla |
| Genzyme Corporation | $44.39 | 2025 | |
| Janssen Biotech, INC. | $41.41 | 2025 | Tremfya |
| Lilly USA, LLC | $37.93 | 2024 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.39 | 2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $31.93 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $29.21 | 2025 | Iqirvo |
| Neurocrine Biosciences, INC. | $22.53 | 2023 | Ingrezza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $21.51 | 2025 | Voquezna |
| Exact Sciences Corporation | $19.88 | 2024 | Cologuard Collection Kit |
| Boston Scientific Corporation | $18.51 | 2025 | General - Ep |
| Pfizer INC. | $16.11 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.